- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04660526
RACE-CARS - RAndomized Cluster Evaluation of Cardiac ARrest Systems
July 15, 2026 updated by: Duke University
RAndomized Cluster Evaluation of Cardiac ARrest Systems
RACE-CARS is a real-world cluster-randomized trial designed to evaluate a multifaceted community and health systems intervention aimed to improve outcomes of out-of-hospital cardiac arrest.
RACE-CARS will enroll 50 counties in North Carolina that are estimated to have a total of approximately 20,000 patients with cardiac arrest over a 4-year intervention period.
County "clusters" will be randomized in a 1:1 ratio to intervention versus usual care.
The trial duration is 7 years, which includes a 6-month start-up (including recruitment and randomization) period, a 12-month intervention training phase, a 4-year intervention period, a 12-month follow-up for to assess quality of life in survivors of OHCA, and a 6-month close-out and data analysis period.
Study Overview
Status
Active, not recruiting
Conditions
Intervention / Treatment
- Other: Rapid cardiac arrest recognition that triggers immediate priority EMS/first responder dispatch by 911 operators
- Other: Systematic bystander resuscitation instruction by 911 operators
- Other: Comprehensive community training of lay people in CPR and AED use.
- Other: Optimized first responder performance including earlier use of AEDs.
Study Type
Interventional
Enrollment (Estimated)
20000
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
North Carolina
-
Durham, North Carolina, United States, 27705
- Duke
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Description
Inclusion Criteria:
- OHCA of non-traumatic etiology
- Patients who are pulseless on arrival of a first responder; or patients who become pulseless in the presence of a first responder; OR patients who have a pulse on arrival of EMS, where a successful defibrillation was previously administered by a bystander or first responder.
Exclusion Criteria:
Untreated cardiac arrests, including arrests in which resuscitation efforts are not initiated or are terminated immediately upon arrival of EMS because the patient is not a viable candidate for resuscitation due to:
- injuries incompatible with life,
- the presence of rigor mortis or lividity,
- signs of decomposition, or
- the presence of a valid DNR.
- Private EMS transport that did not involve 911 dispatch (example: interfacility transport between nursing home and hospital).
- Arrest of clear and obvious traumatic etiology
- Bystander suspected cardiac arrest, where ROSC was achieved without the need for defibrillation or first responder CPR
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Health Services Research
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: Intervention (Enhanced Standard of Care)
Mass community CPR/AED training, optimize 911 medical dispatch, improve first responder performance
|
EMS first responders will recognize cardiac arrest and respond immediately, increasing time to dispatch
911 operators will be able to describe how to administer CPR over the phone.
Training of lay people regarding CPR and AED use.
First responders will recognize where AEDs are located and use them appropriately
|
|
No Intervention: Control (Standard of Care)
Usual care, continuing standard quality improvement effort
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Survival with good neurologic outcomes as measured by a CPC score of 1 or 2 at discharge
Time Frame: up to 12months
|
Cerebral Performance Category (CPC)
|
up to 12months
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Percent of patients who receive CPR from a bystander as measured by EMS report
Time Frame: Baseline
|
Baseline
|
|
Rate of Defibrillation before paramedics arrive as measured by bystander interview
Time Frame: Baseline
|
Baseline
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Percent of cardiac arrest patients whose cardiac arrests are recognized by 911-dispatcher through telephone call
Time Frame: Follow-up, up to 4 years
|
Follow-up, up to 4 years
|
|
|
Percent of cardiac arrest patients with responders who receive CPR instructions by 911-dispatcher through telephone call
Time Frame: Follow-up, up to 4 years
|
Follow-up, up to 4 years
|
|
|
Survival rate as measured by medical record abstraction
Time Frame: Follow-up, up to 4 years
|
Follow-up, up to 4 years
|
|
|
Change in Neurologic disability as measured by Modified Rankin Score
Time Frame: 3 months, 12 months
|
The Modified Rankin Score is a 6 point likert scale, with 0 being "No symptoms" and 6 being "Dead"
|
3 months, 12 months
|
|
Change in Quality of life as measured by the SF-36
Time Frame: 3 months, 12 months
|
The SF-36 is Is a health-related quality-of-life questionnaire consisting of thirty six questions that measure eight health domains to assess physical and mental health.
Physical health-related domains include General Health (GH), Physical Functioning (PF), Role Physical (RP), and Body Pain (BP).
|
3 months, 12 months
|
|
Change in Quality of life as measured by the EQ-5D-5L
Time Frame: 3 months, 12 months
|
The EQ-5D-5L is Quality of Life instrument measure with one question for each of the five dimensions that include mobility, self-care, usual activities, pain/discomfort, and anxiety/depression.
|
3 months, 12 months
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Collaborators
Investigators
- Principal Investigator: Christopher Granger, MD, Duke University
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
July 1, 2022
Primary Completion (Estimated)
August 31, 2026
Study Completion (Estimated)
June 30, 2027
Study Registration Dates
First Submitted
December 3, 2020
First Submitted That Met QC Criteria
December 3, 2020
First Posted (Actual)
December 9, 2020
Study Record Updates
Last Update Posted (Actual)
July 16, 2026
Last Update Submitted That Met QC Criteria
July 15, 2026
Last Verified
July 1, 2026
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- Pro00105633
- 5UH3HL146935-06 (U.S. NIH Grant/Contract)
- 5U24HL146938-06 (U.S. NIH Grant/Contract)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.